Show simple item record

dc.contributor.authorVan Den Neste, E
dc.contributor.authorSchmitz, N
dc.contributor.authorMounier, N
dc.contributor.authorGill, D
dc.contributor.authorLinch, D
dc.contributor.authorTrneny, M
dc.contributor.authorMilpied, N
dc.contributor.authorRadford, John A
dc.contributor.authorKetterer, N
dc.contributor.authorShpilberg, O
dc.contributor.authorDührsen, U
dc.contributor.authorMa, D
dc.contributor.authorBrière, J
dc.contributor.authorThieblemont, C
dc.contributor.authorSalles, G
dc.contributor.authorMoskowitz, C
dc.contributor.authorGlass, B
dc.contributor.authorGisselbrecht, C
dc.date.accessioned2015-10-26T10:48:20Zen
dc.date.available2015-10-26T10:48:20Zen
dc.date.issued2015-09-14en
dc.identifier.citationOutcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. 2015: Bone Marrow Transplanten
dc.identifier.issn1476-5365en
dc.identifier.pmid26367239en
dc.identifier.doi10.1038/bmt.2015.213en
dc.identifier.urihttp://hdl.handle.net/10541/581089en
dc.description.abstractSalvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second-line treatment for relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, the strategy is less clear in patients who require third-line treatment. Updated outcomes of 203 patients who could not proceed to scheduled ASCT in the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) are herein reviewed. In the intent-to-treat analysis, overall response rate to third-line chemotherapy was 39%, with 27% CR or CR unconfirmed, and 12% PR. Among the 203 patients, 64 (31.5%) were eventually transplanted (ASCT 56, allogeneic SCT 8). Median overall survival (OS) of the entire population was 4.4 months. OS was significantly improved in patients with lower tertiary International Prognostic Index (IPI), patients responding to third-line treatment and patients transplanted with a 1-year OS of 41.6% compared with 16.3% for the not transplanted (P<0.0001). In multivariate analysis, IPI at relapse (hazard ratio (HR) 2.409) and transplantation (HR 0.375) independently predicted OS. Third-line salvage chemotherapy can lead to response followed by transplantation and long-term survival in DLBCL patients. However, improvement of salvage efficacy is an urgent need with new drugs.Bone Marrow Transplantation advance online publication, 14 September 2015; doi:10.1038/bmt.2015.213.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Bone marrow transplantationen
dc.titleOutcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.en
dc.typeArticleen
dc.contributor.departmentCliniques Universitaires UCL Saint-Luc, Brussels, Belgiumen
dc.identifier.journalBone Marrow Transplantationen
dc.description.collectionLymphoma Research Teamen
html.description.abstractSalvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second-line treatment for relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, the strategy is less clear in patients who require third-line treatment. Updated outcomes of 203 patients who could not proceed to scheduled ASCT in the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) are herein reviewed. In the intent-to-treat analysis, overall response rate to third-line chemotherapy was 39%, with 27% CR or CR unconfirmed, and 12% PR. Among the 203 patients, 64 (31.5%) were eventually transplanted (ASCT 56, allogeneic SCT 8). Median overall survival (OS) of the entire population was 4.4 months. OS was significantly improved in patients with lower tertiary International Prognostic Index (IPI), patients responding to third-line treatment and patients transplanted with a 1-year OS of 41.6% compared with 16.3% for the not transplanted (P<0.0001). In multivariate analysis, IPI at relapse (hazard ratio (HR) 2.409) and transplantation (HR 0.375) independently predicted OS. Third-line salvage chemotherapy can lead to response followed by transplantation and long-term survival in DLBCL patients. However, improvement of salvage efficacy is an urgent need with new drugs.Bone Marrow Transplantation advance online publication, 14 September 2015; doi:10.1038/bmt.2015.213.


This item appears in the following Collection(s)

Show simple item record